KalVista Pharmaceuticals (KALV) Total Liabilities (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Total Liabilities of $174.7 million in Q3 2025, up 12.44% quarter-over-quarter from $155.4 million in Q2 2025, and up 537.67% year-over-year from $27.4 million in Q3 2024.
KalVista Pharmaceuticals' Total Liabilities history runs 12 years deep, the most recent figure standing at $174.7 million for Q3 2025.
- In Q3 2025, Total Liabilities rose 537.67% year-over-year to $174.7 million; the TTM figure through Jul 2025 stood at $174.7 million (up 537.67% YoY), while the FY2025 annual figure was $155.4 million, up 439.1% from the prior year.
- Total Liabilities came in at $174.7 million for Q3 2025 at KalVista Pharmaceuticals, up from $155.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $174.7 million in Q3 2025 to a low of $7.6 million in Q1 2021.
- A 5-year average of $41.1 million and a median of $21.0 million in 2023 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities plunged 42.06% in 2021 and surged 537.67% in 2025, its largest moves.
- KalVista Pharmaceuticals' Total Liabilities stood at $16.3 million in 2021, then grew by 16.45% to $19.0 million in 2022, then grew by 27.71% to $24.3 million in 2023, then surged by 436.93% to $130.5 million in 2024, then jumped by 33.93% to $174.7 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $174.7 million, $155.4 million, and $130.5 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 174.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 174.72 Mn |
| Apr 30, 2025 | 155.38 Mn |
| Dec 31, 2024 | 130.46 Mn |
| Oct 31, 2024 | 26.84 Mn |
| Jul 31, 2024 | 27.40 Mn |
| Apr 30, 2024 | 28.82 Mn |
| Jan 31, 2024 | 25.39 Mn |
| Oct 31, 2023 | 24.30 Mn |
| Jul 31, 2023 | 21.00 Mn |
| Apr 30, 2023 | 22.18 Mn |
| Jan 31, 2023 | 19.03 Mn |
| Oct 31, 2022 | 19.03 Mn |
| Jul 31, 2022 | 17.75 Mn |
| Apr 30, 2022 | 18.79 Mn |
| Jan 31, 2022 | 17.12 Mn |
| Oct 31, 2021 | 16.34 Mn |
| Jul 31, 2021 | 14.70 Mn |
| Apr 30, 2021 | 14.82 Mn |
| Jan 31, 2021 | 7.64 Mn |
| Oct 31, 2020 | 10.47 Mn |
| Jul 31, 2020 | 9.47 Mn |
| Apr 30, 2020 | 8.78 Mn |
| Jan 31, 2020 | 13.19 Mn |
| Oct 31, 2019 | 14.28 Mn |
| Jul 31, 2019 | 18.02 Mn |
| Apr 30, 2019 | 21.39 Mn |
| Jan 31, 2019 | 22.49 Mn |
| Oct 31, 2018 | 25.61 Mn |
| Jul 31, 2018 | 31.37 Mn |
| Apr 30, 2018 | 34.14 Mn |
| Jan 31, 2018 | 38.09 Mn |
| Oct 31, 2017 | 3.66 Mn |
| Jul 31, 2017 | 4.05 Mn |
| Apr 30, 2017 | 3.02 Mn |
| Jan 31, 2017 | 3.20 Mn |
| Mar 31, 2016 | 6.60 Mn |
| Dec 31, 2015 | 7.48 Mn |
| Sep 30, 2015 | 7.46 Mn |
| Jun 30, 2015 | 8.27 Mn |
| Mar 31, 2015 | 17.13 Mn |
| Dec 31, 2014 | 11.27 Mn |